CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Nursing Coordination Invaluable to Successful Delivery of CAR T Therapy

February 26th 2017

Proper care coordination and patient education are essential to the success of delivering chimeric antigen receptor T-cell therapy, particularly in preparing patients for potential adverse events.

Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma

February 26th 2017

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Dr. Neelapu on ZUMA-1 Trial Design of KTE-C19

February 17th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the design of the ZUMA-1 trial of the chimeric antigen receptor (CAR) T-cell therapy KTE-C19 for patients with aggressive lymphomas.

Dr. Chaudhary on Short-Term and Long-Term Future of CAR T-Cells

February 14th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the short-term and long-term future of CAR T-cells.

Top Centers Exploring JCAR017 for Non-Hodgkin Lymphoma

February 13th 2017

After demonstrating early success in acute lymphoblastic leukemia, CAR T-cell therapies are now expanding into all areas of hematologic malignancies, including non-Hodgkin lymphoma.

Ibrutinib Could Enhance CAR T-Cell Treatment Impact in CLL

February 10th 2017

Treatment with concurrent ibrutinib improves expansion of chimeric antigen receptor T-cells and could subsequently improve response in patients with chronic lymphocytic leukemia, according to a study presented during the 2017 ASH Annual Meeting.

Study Identifies Potential Biomarkers for CAR T-Cell Therapy Response in CLL

February 10th 2017

A study presented at the 2016 ASH Annual Meeting identified potential biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia.

Dr. Neelapu on Next Steps With KTE-C19 in Lymphoma

February 2nd 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps with KTE-C19, an anti-CD19 chimeric antigen receptor T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Novel CAR T-cell Combos on Horizon for Hematologic Malignancies

January 31st 2017

Novel combination approaches are being explored that hope to capitalize on the high rates of complete remissions seen with CAR T-cell therapies for patients with hematologic malignancies.

Dr. Chaudhary on Remaining Challenges With CAR T-Cell Therapy

January 25th 2017

Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses challenges that oncologists continue to face when treating patients with CAR T-cell therapy.

Dr. Neelapu on the Safety Profile of KTE-C19 in Patients With Lymphoma

January 12th 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the safety profile of KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Dr. Chaudhary on History of CAR T-Cell Therapy

January 11th 2017

Expert Highlights Efficacy of KTE-C19 CAR T-Cell Therapy in Non-Hodgkin Lymphoma

January 6th 2017

KTE-C19, an investigational CAR T-cell therapy, recently demonstrated positive results for patients with chemorefractory aggressive non-Hodgkin lymphoma.

KTE-C19 Leads to High Response Rates in Refractory NHL

December 7th 2016

Almost 80% of patients with treatment-refractory non-Hodgkin lymphoma had objective responses following treatment with KTE-C19, a chimeric antigen receptor T-cell therapy targeting CD19.

CTL019 Highly Effective in Global Phase II ALL Study, FDA Submission Anticipated

December 4th 2016

The CAR T-cell therapy CTL019 demonstrated an 82% complete remission (CR) or CR with incomplete blood count recovery rate for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Anti-CD22 CAR T-Cell Salvage Therapy Succeeds in Pediatric ALL

December 4th 2016

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy induced an 80% complete remission rate among children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia, many of whom had prior anti-CD19 CAR T-cell therapy.

Anti-BCMA CAR T-Cell Therapy Approaches 80% Response in Myeloma

December 2nd 2016

An investigational anti-BCMA chimeric antigen receptor T-cell therapy demonstrated an objective response rate of 78% in patients with relapsed/refractory multiple myeloma.

CLL Landscape to Change Dramatically Over Next Decade

November 21st 2016

Standard treatment approaches for patients with chronic lymphocytic leukemia will continue to include fludarabine, cyclophosphamide, and rituximab and allogeneic stem cell transplantation.

From Hospice to Remission: Hopes Remain High for CAR Therapies

October 28th 2016

Patients with advanced lymphoid malignancies have had few treatment options, particularly those with extensive, refractory disease. Allogeneic or autologous hematopoietic stem cell transplantation has been one life-prolonging and potentially curative option for these patients, but these procedures are associated with various toxicities and are not appropriate for all patients, with older adults and those with great- er disease burden often excluded as candidates.

Expert Describes Importance of Classifying T-Cell Lymphomas

October 28th 2016

Novel agents being explored in the landscape of both peripheral and cutaneous T-cell lymphomas could lead to an expansion of treatment options for patients.